Deutsche Bank AG Invests $857,000 in Replimune Group, Inc. $REPL

Key Points

• Deutsche Bank initiated a position in Replimune Group, purchasing 77,455 shares worth approximately $857,000, while institutional investors and hedge funds collectively own 92.53% of the company.
• Replimune shares opened at $15.30 after declining 1.3%; the stock has risen sharply from its $1.50 one-year low and trades near its $16.15 high. The company reported a quarterly loss of $0.72 per share, missing estimates by $0.03.
• Analyst sentiment is generally positive, with the stock carrying a “Moderate Buy” consensus rating and a $12 average price target. However, insiders sold shares recently, including sales by the CFO and another insider to cover tax obligations related to vested equity awards.

Deutsche Bank AG purchased a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 77,455 shares of the company's stock, valued at approximately $857,000. Deutsche Bank AG owned approximately 0.09% of Replimune Group as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the company. RTW Investments LP boosted its position in Replimune Group by 11.6% during the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company's stock worth $69,404,000 after acquiring an additional 744,620 shares during the last quarter. State Street Corp grew its position in shares of Replimune Group by 26.3% in the fourth quarter. State Street Corp now owns 3,693,107 shares of the company's stock valued at $35,897,000 after purchasing an additional 768,982 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Replimune Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company's stock valued at $14,579,000 after purchasing an additional 9,707 shares in the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company's stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the last quarter. Finally, Toronto Dominion Bank increased its holdings in shares of Replimune Group by 62.5% in the fourth quarter. Toronto Dominion Bank now owns 2,229,527 shares of the company's stock valued at $21,671,000 after purchasing an additional 857,475 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Trading Down 1.3%

REPL opened at $15.30 on Tuesday. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $16.15. The stock has a market capitalization of $1.44 billion, a PE ratio of -4.86 and a beta of 0.88. The business's 50 day moving average price is $11.92 and its 200 day moving average price is $8.40. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, equities research analysts expect that Replimune Group, Inc. will post -2.81 EPS for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,256 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares of the company's stock, valued at $3,082,366.56. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the transaction, the insider directly owned 224,215 shares of the company's stock, valued at approximately $2,908,068.55. This trade represents a 4.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock valued at $1,038,364 in the last quarter. Corporate insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on REPL. BMO Capital Markets raised Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research note on Tuesday, June 30th. Wall Street Zen raised Replimune Group from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 23rd. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target on the stock in a report on Friday, August 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Replimune Group in a research report on Wednesday, August 12th. Finally, Leerink Partners raised shares of Replimune Group from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.00.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source